Cordis Bilateral AAA Device Compared to Open Surgical Repair of Abdominal Aortic Aneurysms (ARIBA)
An Evaluation of the Safety and Effectiveness of the Cordis Bilateral AAA Device Compared to Open Surgical Repair for the Treatment of Abdominal Aortic Aneurysm
1 other identifier
interventional
29
1 country
1
Brief Summary
The objective of this study is to assess the safety and effectiveness of the Cordis Bilateral AAA device and its Delivery System compared to open surgical repair for the treatment of Abdominal Aortic Aneurysm (AAA).
Trial Health
Trial Health Score
Automated assessment based on enrollment pace, timeline, and geographic reach
participants targeted
Target at P25-P50 for phase_1
Started Dec 1999
Longer than P75 for phase_1
1 active site
Health score is calculated from publicly available data and should be used for screening purposes only.
Trial Relationships
Click on a node to explore related trials.
Study Timeline
Key milestones and dates
Study Start
First participant enrolled
December 1, 1999
CompletedFirst Submitted
Initial submission to the registry
October 6, 2005
CompletedFirst Posted
Study publicly available on registry
October 10, 2005
CompletedStudy Completion
Last participant's last visit for all outcomes
February 1, 2006
CompletedDecember 9, 2005
October 1, 2005
October 6, 2005
December 8, 2005
Conditions
Outcome Measures
Primary Outcomes (2)
Primary success is defined as freedom from all of the following: rupture of aneurysm, enlargement of aneurysm > 0.5 cm on CT scan, with or without endoleak, as compared to any previous measurement, symptomatic aneurysm requiring treatment.
The absence of major complications at thirty days defined as arterial thrombosis, respiratory impairment, renal failure, myocardial infarction (M.I.) and stroke in combination with the absence of major complications at one year.
Secondary Outcomes (1)
· Technical success defined as the successful access and deployment of the device at the appropriate anatomic location with aneurysmal exclusion determined by angiography at the time of deployment.
Interventions
Eligibility Criteria
You may qualify if:
- \- Anatomic (stent-graft)
- Aortic Aneurysm Diameter
- \> 4.5 cm
- Those aortic aneurysms \< 4.5 cm that are at least 1.5 times the diameter of the aorta with a size increase of 5 mm or greater over a six month period will also be included for possible treatment.
- Aorto-iliac aneurysms in which the aortic aneurysm is \< 4.5 cm but the iliac artery aneurysms are \> 3.0 cm in diameter or there is evidence of recent expansion (5 mm or greater over a six month period) in iliac aneurysms \< 3.0 cm.
- Saccular aortic aneurysms \> 3.0 cm.
- Aortic Neck
- Diameter \> 17 mm and \< 28 mm (Phase I)
- Diameter \> 14 mm and \< 28 mm (Phase II)
- Angulation Neck Length \< 45° \> 15 mm \<60° \> 25 mm
- Iliac Arteries
- Diameter \> 8 mm and \< 18 mm (Phase I and Phase II)
- At least one common iliac artery with a cuff \> 15 mm.
- Diameter Aortic Neck Common Iliac 26-28 mm 13-18 mm 23-25.9 mm 10-17 mm 20-22.9 mm 9-15 mm 17-19.9 mm 8-13 mm 14-16.9 mm 8-11mm
- \*NOTE: An aortic diameter cannot be treated if the iliac diameter is not in the same range (e.g. 26-28 mm aortic necks must be in conjunction with 13-18 mm common iliacs).
- +9 more criteria
You may not qualify if:
- Anatomic (stent-graft)
- Aortic Aneurysm Diameter
- · \< 4.5 cm that are not at least 1.5 times the diameter of the aorta with evidence of a size increase of 5 mm or greater within a six month period.
- Aorto-iliac Aneurysms
- \< 3.0 cm in diameter unless evidence of recent expansion (5 mm or greater within a six month period).
- The iliac portion of the aneurysm extending to the bifurcation bilaterally which would necessitate covering both internal iliac arteries with the device.
- Aortic Neck
- Diameter \< 17 mm and \> 28 mm (Phase I)
- Diameter \< 14 and \>28 (Phase II)
- Thrombus lined
- Highly calcified
- Iliac Arteries
- \< 8 mm and \> 18 mm (native) (Phase I and Phase II)
- Highly calcified (common)
- Neither common iliac artery with a cuff \> 15 mm.
- +9 more criteria
Contact the study team to confirm eligibility.
Sponsors & Collaborators
- Cordis US Corp.lead
Study Sites (1)
Mt. Sinai Hospital
New York, New York, 10029, United States
MeSH Terms
Conditions
Condition Hierarchy (Ancestors)
Study Officials
- PRINCIPAL INVESTIGATOR
Michael Marin, MD
MOUNT SINAI HOSPITAL
Study Design
- Study Type
- interventional
- Phase
- phase 1
- Allocation
- NON RANDOMIZED
- Masking
- NONE
- Purpose
- TREATMENT
- Intervention Model
- PARALLEL
- Sponsor Type
- INDUSTRY
Study Record Dates
First Submitted
October 6, 2005
First Posted
October 10, 2005
Study Start
December 1, 1999
Study Completion
February 1, 2006
Last Updated
December 9, 2005
Record last verified: 2005-10